Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 10/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170502 | 0.88 | ADA (0.48) | ADASLC6A4 | |
| SCHEMBL6174709 | 0.88 | ADA (0.44) | ADALPAR1 | |
| SCHEMBL6168401 | 0.86 | ADA (0.59) | ADA | |
| SCHEMBL6133844 | 0.85 | ADA (0.38) | ADA | |
| SCHEMBL6172025 | 0.85 | LPAR1 (0.42) | ADALPAR1 | |
| SCHEMBL1385827 | 0.85 | ADA (0.42) | ADALPAR1 | |
| SCHEMBL6133830 | 0.85 | ADA (0.42) | ADALPAR1 | |
| SCHEMBL6171094 | 0.85 | ADA (0.40) | ADA | |
| SCHEMBL6170042 | 0.85 | ADA (0.54) | ADALPAR1 | |
| SCHEMBL6134341 | 0.84 | ADA (0.41) | ADALPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| EP-1098885-B9 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-05-18 | — | — | EP | disclosed |
| EP-1098885-B1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6359145-B1 | ADENOSINE DEAMINASE INHIBITOR; ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ADA, AMPD2, AMPD1 | ADA 1/4885TAAR1 1773/4885LPAR1 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.